目的 觀察普拉洛芬聯(lián)合氯替潑諾治療白內(nèi)障患者術后炎癥的臨床療效。方法 選取2013年9月-2015年5月延安大學附屬醫(yī)院收治的白內(nèi)障手術患者156例，隨機分為對照組和治療組，每組各78例。對照組在術后采用氯替潑諾混懸滴眼液治療，治療組在對照組的基礎上采用普拉洛芬滴眼液治療，給藥方式均為術后一周內(nèi)2滴/次，6次/d，一周后減為2滴/次，4次/d。兩組均連續(xù)給藥兩周。比較術后第3、7、15、30天兩組患者的炎癥評分、眼壓、黃斑中心凹視網(wǎng)膜厚度（CMT）以及不良反應情況。結果 術后第3、7、15天，兩組的炎癥評分均高于術前，同組治療前后差異均有統(tǒng)計學意義（P<0.05）；治療組術后第3、7、15、30天的炎癥評分均顯著低于同期對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。術后第7、15天，對照組的眼壓均高于術前，同組治療前后差異均有統(tǒng)計學意義（P<0.05）；治療組術后第7、15天的眼壓均顯著低于同期對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。術后第7、15、30天，兩組的CMT均顯著高于術前，同組治療前后差異均有統(tǒng)計學意義（P<0.05）；治療組術后第7、15、30天的CMT均顯著低于同期對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療組和對照組的不良反應發(fā)生率分別為24.36%、44.87%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 普拉洛芬聯(lián)合氯替潑諾對白內(nèi)障術后抗炎效果顯著，且可以降低眼壓的升高，改善黃斑中心凹視網(wǎng)膜厚度，安全性高，具有一定的臨床推廣應用價值。

Objective To observe the clinical efficacy of pranoprofen combined with loteprednol in treatment of post-operative inflammation for patients with cataract. Methods Patients (156 cases) with cataract surgery in Yanan University Affiliated Hospital from September 2013 to May 2015 were randomly divided into control and treatment groups. Each group had 78 cases. Patients in the control group were given Loteprednol Etabonate Ophthalmic Suspension after surgery, while patients in the treatment group were given Pranoprofen Eye Drops on the basis of the control group. The administration methods were 2 drops/time in the first week after surgery, six times daily. After 1 week, the dosage was reduced to 2 drops/time, four times daily. Inflammatory scores, intraocular pressure, central macular thickness, and adverse reactions in two groups on the third, 7^th, 15^th, and 30^th day after surgery were compared. Results On the third, 7^th, and 15^th day after surgery, inflammatory scores in two groups were higher than those before surgery, and there were differences between two groups (P<0.05). Inflammatory scores in the treatment group on the third, 7^th, 15^th, and 30^th day after surgery were lower than those in the control group in the same period with significant difference between two groups (P<0.05). On the 7^th and 15^th day after surgery, intraocular pressure in the control group was higher than that before surgery, and there were differences between two groups (P<0.05). Intraocular pressure in the treatment group on the third, 7^th, and 15^th after surgery was lower than those in the control group in the same period, with significant difference between two groups (P<0.05). On the 7^th and 15^th day after surgery, CMT in two groups were higher than those before surgery, and there were differences between two groups (P<0.05).CMT in the treatment group on the 7^th, 15^th, and 30^th after surgery was lower than those in the control group in the same period, and the difference was statistically significant between two groups (P<0.05). The adverse reaction rates in the treatment and control groups were 24.36% and 44.87%, respectively, and there were significant difference between two groups (P<0.05). Conclusions Pranoprofen combined with loteprednol has a significant clinical effect in treatment of post-operative inflammation for patients with cataract, can reduce the increase of intraocular pressure, and improve CMT with high security, which has a certain clinical application value.